On this page
Quick Reference
Overview and Recommendations
Background
- • and are overlapping names for a chronic, disabling, multisystem illness commonly called . Do not diagnose it from fatigue alone; the defining pattern includes (PEM), substantial functional reduction, and additional sleep, cognitive, or autonomic symptoms.
- • is delayed, disproportionate worsening after physical, cognitive, emotional, sensory, or orthostatic activity, with recovery that may take days or weeks. Ordinary tiredness that resolves with usual rest does not establish ME/CFS.
- •The core phenotype combines reduced function, unrefreshing sleep, cognitive impairment, and . Patients may also have pain, headache, sensory hypersensitivity, flu-like symptoms, gastrointestinal symptoms, and a fluctuating or relapsing course.
- •No validated biomarker establishes or excludes . Candidate abnormalities in immune, metabolic, autonomic, vascular, exercise, sensory, and neuroimaging studies remain investigational, so diagnosis depends on the clinical pattern and evaluation for better alternative explanations.
- •Apply one case definition transparently. permits diagnosis after at least 3 months when debilitating fatigue worsened by activity, PEM, unrefreshing sleep, cognitive difficulty, functional reduction, and no better explanation are present; NAM/CDC generally uses at least 6 months in adults and 3 months in children and adolescents, while the Canadian Consensus Criteria (CCC) require a broader multisystem phenotype and generally at least 6 months in adults.
Evaluation
- •Establish the change from pre-illness baseline by documenting reliable usual function, not the patient’s best day. Record effects on self-care, domestic tasks, mobility, work or school, communication, social participation, and the assistance or recovery each task requires.
- •Characterize PEM with an event-based history. Ask what activity preceded worsening, whether the trigger was physical, cognitive, emotional, sensory, or upright, when symptoms began, which symptoms changed, how long recovery took, and whether baseline returned.
- •Assess sleep, cognition, and upright tolerance separately. Ask whether sleep restores function; assess attention, processing speed, memory, word finding, and multitasking; and ask whether standing causes dizziness, palpitations, weakness, nausea, visual dimming, presyncope, or syncope that improves when lying down.
- •Record onset and course, including preceding infection, surgery, trauma, pregnancy, medication change, sleep disruption, or other illness, but treat chronology as a clue rather than proof of causation. Infectious mononucleosis, COVID-19, influenza-like illness, and other physiologic stressors may precede illness without proving a persistent infection or a specific cause.
- •Examine without provoking deterioration. Use a quiet, low-stimulation setting, allow pauses, minimize transfers and prolonged upright activity, and interpret a normal brief examination cautiously because it does not measure sustained capacity or delayed post-exertional worsening.
- •Measure orthostatic heart rate and blood pressure only when clinically safe and tolerated, recording posture, duration, symptoms, and reason for stopping. In one ME/CFS cohort, was defined as a heart-rate increase of at least 30 beats/min or an absolute heart rate of at least 120 beats/min during a 10-minute lean test; do not insist on prolonged standing or maximal exercise testing.
- •Investigate plausible alternatives with a targeted initial panel for persistent unexplained fatigue: , ferritin, electrolytes, renal function, liver function, calcium, glucose or , , or , and urinalysis. Add a pregnancy test when pregnancy is possible, and order B12, folate, vitamin D, CK, or infectious serology only when the history or examination supports them.
- •Use ECG, ambulatory monitoring, echocardiography, chest imaging, pulmonary function testing, sleep testing, neurological imaging, or nerve studies only when symptoms, examination, or initial results provide an indication. Investigate chest pain, dyspnea at rest, hypoxemia, sustained syncope, focal neurological deficit, delirium, rapidly progressive weakness, severe dehydration, bleeding, hemodynamic instability, suicidal intent, or unexplained fever urgently.
- •Do not use a positive antibody result, abnormal autonomic test, illness trigger, or proposed biomarker as the diagnosis. Do not use normal routine tests to invalidate functional impairment or a nonspecific abnormality as proof of ME/CFS; reassess unexpected or borderline results and continue evaluation if new focal, abrupt, severe, or progressive symptoms emerge.
- •When duration or criterion coverage is incomplete, document a provisional diagnosis and a reassessment plan rather than forcing certainty. A daily record of activity, PEM latency, symptom change, recovery, sleep, cognition, upright tolerance, and assistance can clarify fluctuating illness without deliberately provoking PEM.
Management
- •Protect the patient’s current activity envelope: the total physical, cognitive, emotional, sensory, social, and upright demand that can be repeated without delayed worsening. Set it from reliable usual function, not a single good day, and review it as symptoms change.
- •Use individualized energy management rather than a quota. Fragment tasks, alternate higher- and lower-demand activities, sit or lie down for tasks when possible, plan rest before predictable exertion, delegate or simplify essential work, and use equipment that reduces upright or sensory demand.
- •During PEM or a crash, stop attempts to maintain the previous schedule. Reduce activity to essential hydration, nutrition, toileting, medicines, communication, and safety; lower sensory and cognitive input; use recumbent or supported positions; and resume other activities only after symptoms stabilize, beginning at the newly tolerated level.
- •Do not prescribe or any generic fixed-increment activity programme. advises against GET and fixed incremental activity or exercise; any physical activity programme offered in selected cases must remain within the person’s energy limit and be delivered by a physiotherapist in an ME/CFS specialist team.
- •If activity is increased after sustained stability, change one demand at a time by the smallest practicable amount and observe the usual delayed-worsening window. If symptoms worsen, return to the last stable level; the endpoint is durable participation within the activity envelope, not normalization of exercise capacity.
- •Start one symptom intervention at a time, use the lowest reasonable dose, and review delayed effects over several days. Stop or reduce treatment that worsens sedation, cognition, orthostatic symptoms, sleep, nausea, or PEM; symptom treatments are not disease-modifying therapies.
- •For sleep, address the sleep phenotype, medication and substance effects, circadian disruption, , and . A cautious trial for circadian delay or sleep initiation is melatonin 0.5-3 mg orally 1-2 hours before the desired bedtime for 2-4 weeks; avoid routine benzodiazepines and sedating antihistamines because of dependence, falls, cognitive effects, and orthostatic hypotension.
- •Treat pain by phenotype and preserve the activity envelope. Options include acetaminophen 500-1000 mg orally every 6-8 hours as needed, not exceeding 3,000 mg/day in routine use, or ibuprofen 200-400 mg orally every 6-8 hours with food for the shortest course when clinically appropriate; avoid NSAIDs with active gastrointestinal bleeding or ulcer disease, significant kidney disease, decompensated heart failure, uncontrolled hypertension, high bleeding risk, or contraindicated pregnancy.
- •For orthostatic intolerance, reduce upright exposure, use slow position changes, cooling, compression, calf activation, and seated or recumbent activity. Increase fluids, often toward 2-3 L/day, and salt only when hypertension, kidney disease, heart failure, hypernatremia, or another contraindication is absent; refer for syncope, marked tachycardia, hypotension, arrhythmia, diagnostic uncertainty, or failure of conservative measures.
- •When persistent orthostatic symptoms warrant medication, specialist or clinician-directed options include fludrocortisone 0.05-0.1 mg orally each morning, titrated to 0.2 mg/day, or midodrine 2.5-5 mg orally three times daily while awake, increased to 10 mg three times daily. Monitor for supine hypertension, potassium abnormalities, edema, urinary retention, and other drug-specific adverse effects.
- •Treat gastrointestinal, allergic, endocrine, inflammatory, sleep, mood, migraine, fibromyalgia, and other coexisting conditions on their own diagnostic evidence. For example, polyethylene glycol 17 g orally daily can be used for constipation, while short-term loperamide can be used for selected diarrhea at 2 mg after the first loose stool and 2 mg after each subsequent stool, up to 8 mg/day, when fever, blood, inflammatory diarrhea, and ileus are absent.
- •Reconcile every prescribed, over-the-counter, supplemental, hormonal, intermittent, and recreational substance at each substantial review. Reduce anticholinergic, sedating, hypotensive, and stimulating burden where possible, and taper drugs that can cause withdrawal rather than stopping them abruptly.
- •Adapt care to severity and access needs. Offer telemedicine, home or collateral assessment, longer appointments, quiet and dim rooms, permission to lie down, scheduled pauses, accessible toilets, written questions, communication aids, and a support person when desired; severe or very severe illness may require home-based care, nutrition support, pressure-care planning, and safeguarding review.
- •Do not prescribe routine antimicrobials, antivirals, immunomodulators, intravenous immunoglobulin, rituximab, metabolic agents, or stimulants solely for an ME/CFS diagnosis. Treat a documented infection or separately established immune-mediated disease according to its own indication, and keep experimental therapy within appropriate research governance.
- •Follow patients longitudinally using sustainable function, PEM frequency and recovery, sleep, orthostatic symptoms, nutrition, medication effects, comorbidities, mood, safety, carer capacity, and work or education demands. Repeat the same measures under comparable conditions, and reassess urgently when new focal, abrupt, severe, progressive, or qualitatively different symptoms appear.
Deep Dive — Evidence Details
Definition, Nomenclature, and Core Clinical Concept
- ▸PEM, functional decline, and unrefreshing sleep are the core recognition triad.
- ▸Document which case definition and duration threshold were applied.
Core diagnosis
and are overlapping terms for a disabling multisystem illness; ME/CFS is not uncomplicated chronic fatigue. The key discriminator is (PEM): delayed, disproportionate worsening after physical, cognitive, emotional, sensory, or orthostatic stress, with prolonged recovery. Diagnosis is clinical because no validated biomarker confirms or excludes ME/CFS. [1][3][14]
Shared features are substantial functional reduction, PEM, unrefreshing sleep, and cognitive or autonomic symptoms. NAM/CDC requires reduced function, PEM, unrefreshing sleep, plus cognitive impairment or , usually for ≥6 months in adults and ≥3 months in children. NICE requires debilitating activity-worsened fatigue, PEM, unrefreshing sleep, cognitive difficulty, reduced function, and ≥3 months’ symptoms. CCC additionally requires pain, neurological/cognitive symptoms, and autonomic, neuroendocrine, or immune features. [1][5][7][8]
Pearl: Do not diagnose ME/CFS from chronic fatigue alone. Ask what happens after exertion, when the worsening begins, how long recovery takes, whether sleep restores function, and whether cognition or upright posture reliably worsens symptoms. [1]
Triggers, Biology, and Epidemiology
- ▸Postinfectious onset is common, but no universal persistent pathogen or validated genetic test exists.
- ▸Epidemiologic estimates are strongly shaped by diagnostic access and ascertainment.
Triggers and proposed biology
ME/CFS commonly follows infectious mononucleosis, , , influenza-like illness, or another viral syndrome, but infection is a precipitant rather than proof of persistent infection. Severity after infectious mononucleosis predicted some long-term cases, while many recovered. [3][25] Noninfectious physiologic stressors may also precede onset, but chronology does not establish causation. [12]
Proposed mechanisms include immune dysregulation, autonomic and vascular dysfunction, altered cellular energy metabolism, sensory-processing abnormalities, and impaired exertional recovery. Findings remain heterogeneous and nonspecific; conventional inflammatory markers, metabolomics, retinal vascular studies, and cardiopulmonary exercise testing are investigational rather than diagnostic. [1][12][15][26][28][31] Do not prescribe routine antimicrobials, antivirals, immunomodulators, or metabolic drugs solely for ME/CFS. [1][3]
Epidemiology
Reported prevalence varies approximately 0.4-0.6% in general populations, up to 0.75% in pediatric estimates, and 1.3% current clinician-diagnosed U.S. adults in 2021-2022. Ascertainment, case definitions, underdiagnosis, and access strongly affect estimates. Women are diagnosed more often; onset clusters in adolescence and early-to-middle adulthood. Poverty, minority status, rurality, and absence from specialist services should not be interpreted as evidence against the diagnosis. [4][33][34][39]
Callout: Treat documented infection or immune disease on its own evidence; positive EBV serology does not prove active infection or justify antiviral therapy. [3]
Phenotype and Primary-Care Assessment
- ▸Use event-based PEM history rather than a generic fatigue score.
- ▸Document sustainable function and post-activity consequences, not maximum performance.
Symptoms
PEM may follow showering, conversation, reading, screen use, emotional stress, heat, noise, or prolonged standing. It may begin immediately or days later, be disproportionate, and last days to weeks. Ask about trigger, latency, changed symptoms, recovery time, and return to baseline. [12][45] Sleep is prolonged or unstable yet unrefreshing; cognition may involve slowed processing, attention, working memory, word finding, or executive difficulty. causes dizziness, palpitations, weakness, nausea, visual dimming, or cognitive clouding relieved by lying down. Pain, headache, sensory hypersensitivity, flu-like symptoms, and gastrointestinal complaints are common. [5][7][8][9][32]
Examination and function
Compare pre-illness, best-day, usual-day, and bad-day function. Record ADLs, IADLs, mobility, upright time, school/work, communication, sensory tolerance, and caregiver needs. Adapt the examination to the activity envelope; avoid prolonged standing, bright light, repeated transfers, or unnecessary exertion. Measure orthostatic vital signs only when safe; inability to complete the maneuver is clinically relevant. A brief normal interaction does not measure sustained capacity or delayed PEM. [49][50]
Pearl: The clinical signal is the combination of delayed, disproportionate, prolonged activity worsening; unrefreshing sleep; cognitive or orthostatic intolerance; and fluctuating multisystem symptoms, not any single symptom or test. [1][8][15]
Diagnostic Reasoning and Mimics
- ▸Use a small targeted initial panel and interpret results in clinical context.
- ▸A negative test excludes only the disorder it adequately assesses.
Stepwise diagnosis
Establish substantial functional reduction, characterize PEM, confirm unrefreshing sleep and cognitive or orthostatic symptoms, verify duration, and investigate plausible alternatives without requiring exhaustive exclusion. ME/CFS may coexist with , , , , , autoimmune, endocrine, or other disease. [39][68]
Initial investigations for persistent unexplained fatigue commonly include CBC, ferritin, electrolytes, renal and liver function, calcium, glucose or HbA1c, TSH, ESR or CRP, and urinalysis; add pregnancy testing when relevant. Target B12, folate, CK, vitamin D, infectious serology, ECG, sleep studies, imaging, or autonomic testing to clinical clues. Investigate focal weakness, fever, weight loss, bleeding, chest pain, dyspnea, syncope, delirium, or progressive symptoms independently. [42][82][85]
POTS assessment requires safe orthostatic measurements; one cohort used a heart-rate rise ≥30 beats/min or absolute rate ≥120 during a 10-minute lean test. [47] Do not use maximal exercise testing to provoke PEM or confirm ME/CFS. [15]
Pearl: Investigate the symptom that does not fit: progressive focal weakness, objective inflammation, persistent fever, major weight loss, exertional cardiopulmonary symptoms, or orthostatic syncope warrants a new diagnostic pathway even when the patient also has a convincing ME/CFS phenotype.
Severity and Outcome Measurement
- ▸Severity is lost sustainable function, not fatigue intensity alone.
- ▸Repeat the same measures under comparable conditions and document assistance.
Functional severity
NICE categories are practical descriptors: mild illness permits self-care with reduced work or study; moderate illness substantially restricts activity and is often housebound; severe illness is mostly housebound or bed/chair-based with assistance needed; very severe illness is bedbound, dependent for basic care, and highly sensory-sensitive. Severity can differ by domain and fluctuate after PEM, sleep disruption, pain, infection, orthostatic stress, or cognitive demand. [17]
Measure reliable usual capacity, assistance, upright tolerance, communication, sensory load, and delayed recovery. Use activity/symptom diaries, caregiver collateral, DSQ or DSQ-Short Form, PROMIS domains, EQ-5D, or Chalder Fatigue Scale as adjuncts; no single questionnaire stages ME/CFS. Record trigger, latency, symptoms, recovery, and return to baseline. Maximal CPET does not define PEM or disability. [15][51][87][88]
Pearl: Classify severity by what the patient can sustain safely and repeatedly, then verify the classification against delayed post-exertional consequences rather than the task completed during the consultation.
Energy Management and Pacing
- ▸Change one demand at a time and observe the patient’s usual delayed-worsening window.
- ▸A reduction after PEM is a therapeutic adjustment, not treatment failure.
Activity envelope
Pacing keeps physical, cognitive, emotional, sensory, social, and upright demand within the patient’s current repeatable activity envelope. Establish the lowest reliable baseline from usual, not best-day, function and monitor delayed responses. Break tasks into short episodes, alternate demand and recovery, sit or lie down for tasks, delegate, simplify meals and communication, and plan rest before predictable exertion. [90][89]
During PEM, reduce activity to essential hydration, nutrition, toileting, medicines, communication, and safety; lower sensory and cognitive input and resume only after stabilization. Do not prescribe fixed step counts, heart-rate ceilings, or quota-based progression. Pacing is not ; NICE advises against GET and fixed incremental activity programmes. Any physical programme must remain within the energy limit and be specialist-supervised. [90]
Pearl: The endpoint is durable participation within the activity envelope, not normalization of exercise capacity.
Symptom-Directed Treatment
- ▸Treat documented comorbidities on their own evidence; these therapies are not disease-modifying ME/CFS treatments.
- ▸Monitor renal, hepatic, blood-pressure, pregnancy, interaction, and fall risks.
Sleep, pain, and orthostatic intolerance
Treat one target at a time, start low, and review delayed effects. For sleep, consider melatonin 0.5-3 mg 1-2 hours before bed; selected alternatives include doxepin 3-6 mg or trazodone 25-50 mg at bedtime. Evaluate sleep apnea, restless legs, circadian disruption, and medication effects; avoid routine benzodiazepines and sedating antihistamines. [8]
For pain, acetaminophen 500-1000 mg every 6-8 hours as needed, maximum 3,000 mg/day, or short-course ibuprofen 200-400 mg every 6-8 hours with food may be appropriate when safe. Neuropathic options include amitriptyline 5-10 mg nightly, duloxetine 20-30 mg daily, gabapentin 100-300 mg nightly, or pregabalin 25-75 mg nightly, titrated cautiously. Avoid chronic opioids when possible.
For orthostatic symptoms, use fluids, salt when safe, compression, cooling, slow transitions, and recumbent activity. Specialist-supervised options include fludrocortisone 0.05-0.1 mg daily, midodrine 2.5-5 mg three times daily while awake, propranolol 10 mg one to three times daily, or ivabradine 2.5-5 mg twice daily. [90][91][97][107]
Callout: Stop or reduce any treatment that worsens sedation, cognition, orthostasis, or PEM.
Coexisting Conditions and Coordinated Care
- ▸Comorbidity does not invalidate ME/CFS if PEM and the defining pattern persist.
- ▸Coordinate consultants to avoid contradictory activity advice and simultaneous medication changes.
Comorbidity
Separate ME/CFS, confirmed comorbidities, uncertain symptoms, and unresolved red flags. , , , , hypermobility, sleep disorders, allergy-like symptoms, depression, anxiety, pelvic disorders, and may coexist. A new focal, progressive, febrile, bleeding, cardiopulmonary, neurologic, or gastrointestinal symptom requires its own evaluation. [111]
Reconcile all prescriptions, OTC medicines, supplements, hormones, caffeine, alcohol, cannabis, nicotine, and intermittent drugs. Start one treatment at a time and record target, benefit, adverse effects, and impact on PEM. Use one coordinating clinician and share a concise plan stating diagnosis, activity envelope, orthostatic and sensory needs, communication method, medication trials, allergies, and escalation thresholds. Adapt care with telemedicine, home visits, quiet rooms, recumbent positioning, pauses, written instructions, and support people. Carer burden, transport, language, finances, and safeguarding require active assessment. [44][49][131]
Pearl: Treat ME/CFS and the coexisting condition as two clinical realities: preserve the patient’s sustainable activity envelope while investigating and treating every independent disease on its own evidence.
Crashes, Severe Illness, and Escalation
- ▸Do not attribute new fever, hypoxemia, persistent syncope, delirium, bleeding, or progressive weakness to ME/CFS without assessment.
- ▸Pre-alert hospitals to sensory, orthostatic, communication, nutrition, and positioning needs.
Immediate management
A crash is disproportionate worsening after exertional, sensory, emotional, upright, procedural, or cognitive demand; a relapse is more sustained loss of function. Reduce activity immediately to essential intake, medicines, toileting, communication, and safety. Use recumbent positioning, low stimulation, minimal transfers, and the patient’s preferred communication. [76][115]
Same-day assessment is required for inability to maintain hydration, oliguria, dysphagia, significant weight loss, fever, hypoxemia, chest pain, syncope, delirium, focal deficit, rapidly progressive weakness, pressure injury, suspected thrombosis, hemodynamic instability, suicidal intent, abuse, neglect, or no safe caregiver plan. Severe or very severe disease may require home-based care, dietetics, community nursing, pressure care, social care, and specialist nutrition support. If markedly malnourished, monitor phosphate, magnesium, potassium, and fluid status during nutritional increases because refeeding syndrome can cause arrhythmia, delirium, seizures, or cardiac arrest. [115]
Callout: A crash that does not stabilize after removing the trigger, or leaves the patient below baseline, warrants reassessment for infection, dehydration, malnutrition, medication toxicity, cardiovascular or neurologic disease, thrombosis, and safeguarding risk.
Work, Education, Disability, and Access
- ▸Attendance or a one-off task does not establish repeatable sustainable capacity.
- ▸Assistive devices conserve energy and are not evidence of unwillingness to walk.
Participation planning
Plan work and education around reliable sustainable capacity, not best days or fixed attendance quotas. Use staged hours, alternate days, flexible deadlines, reduced workload, planned rest, remote or asynchronous participation, written instructions, dictation, screen modification, quiet low-stimulation spaces, seated work, accessible toilets, nearby parking, mobility aids, and a named contact. Change one demand at a time and review delayed PEM before retaining it. [122][123][124][125]
Document the task, duration, posture, cognitive and sensory load, assistance, symptom latency, recovery, repeatability, and consequences of attempting more. Collateral evidence may include attendance records, employer or teacher observations, care logs, occupational-therapy assessments, and symptom diaries. A brief fluent consultation does not demonstrate capacity for a full workday or school day. [134][135]
Assess carer hours, respite, food and transport access, communication needs, safeguarding, and backup plans. Offer telemedicine, home visits, clustered care, interpreter services, and recumbent transport where needed. Describe accommodations, rationale, review date, and contingency plan rather than merely writing “unable to work.” [127][131][133][137]
Long-Term Course, Prognosis, and Follow-Up
- ▸Investigate new focal, abrupt, severe, progressive, or qualitatively different symptoms independently.
- ▸Use remote and low-burden methods to include housebound and bedbound patients in care and research.
Longitudinal care
ME/CFS is heterogeneous, fluctuating, and often relapsing; current severity does not determine an individual prognosis. In U.S. survey data, 20.7% of adults with a past diagnosis reported no longer having ME/CFS, but 40-50% still had similar symptoms or function, so “recovery” requires clarification and should be judged by durable function across repeated days. [4][18]
At follow-up, reassess PEM latency and recovery, sleep over several nights, orthostatic symptoms, nutrition and weight, swallowing, medication effects, comorbidities, mental health, safeguarding, carers, accommodations, and new red flags. Stable mild/moderate illness may use clinic or video review; severe illness may require home, telephone, asynchronous, or collateral assessment. Repeat comparable outcome measures every 3-6 months when stable, sooner after relapse or treatment change. [8][44]
Research priorities include validated biomarkers, longitudinal multimodal phenotyping, pediatric and severe-disease cohorts, patient-reported outcomes, and trials reporting delayed harms and function rather than immediate fatigue scores. Unproven antivirals, immunomodulators, metabolic agents, and fixed-increment exercise belong in governed research, not routine care. [42][86][120][141]
Callout: Improvement means a larger, reliable activity envelope with fewer or shorter exacerbations, not completion of a rehabilitation schedule.
References
- [1]
Fanò-Illic G, Coscia F, Gigliotti PV et al.. “Pathophysiological, Translational, and Diagnostic Aspects of ME/CFS: A Focus on Skeletal Muscle Involvement.” Diagnostics (Basel, Switzerland) (2026). PMID: 41975732 ↗
Journal Article, ReviewCited in: ME/CFS: Definition, Nomenclature, and the Core Clinical Concept, Infectious Triggers, Predisposition, and Proposed Biology of ME/CFS, The ME/CFS Phenotype: PEM, Sleep, Cognition, Autonomic Symptoms, and Pain - [2]
Fehrer A, Windzio L, Schoening S et al.. “Expert perspectives on Myalgic encephalomyelitis/chronic fatigue syndrome - Insights from the 3rd International Conference of the Charité Fatigue Center.” Autoimmunity reviews (2026). PMID: 41895458 ↗
Journal Article, ReviewCited in: ME/CFS: Definition, Nomenclature, and the Core Clinical Concept, Infectious Triggers, Predisposition, and Proposed Biology of ME/CFS, Crashes, Severe and Very Severe ME/CFS, Safety, and Escalation - [3]
Watton P, Prusty BK. “Reframing ME/CFS: toward a unified mechanistic model of chronic post-infectious diseases.” Journal of translational medicine (2026). PMID: 42174604 ↗
Journal Article, ReviewCited in: ME/CFS: Definition, Nomenclature, and the Core Clinical Concept, Infectious Triggers, Predisposition, and Proposed Biology of ME/CFS, Who Develops ME/CFS: Epidemiology, Risk Context, and Health Inequities - [4]
Fleig K, Nahin R, Stussman B et al.. “Myalgic Encephalomyelitis/Chronic Fatigue Syndrome diagnostic reporting in the 2021-2023 National Health Interview Survey.” BMC public health (2026). PMID: 42104344 ↗
Journal ArticleCited in: ME/CFS: Definition, Nomenclature, and the Core Clinical Concept, Who Develops ME/CFS: Epidemiology, Risk Context, and Health Inequities, Confirming ME/CFS: Case Definitions and Diagnostic Reasoning, Excluding Mimics: Differential Diagnosis and Targeted Primary-Care Investigations, Long-Term Course, Prognosis, Follow-Up, and Research Priorities - [5]
Miwa K. “Orthostatic intolerance with small heart and/or disequilibrium in patients with myalgic encephalomyelitis/chronic fatigue syndrome: clinical update and paradigm shift.” Frontiers in medicine (2026). PMID: 42591853 ↗
Journal Article, ReviewCited in: ME/CFS: Definition, Nomenclature, and the Core Clinical Concept, The ME/CFS Phenotype: PEM, Sleep, Cognition, Autonomic Symptoms, and Pain, Excluding Mimics: Differential Diagnosis and Targeted Primary-Care Investigations, Symptom-Directed Treatment: Sleep, Pain, Orthostatic Intolerance, and Comorbid Symptoms, Coexisting Conditions and Coordinated Family-Medicine Care, Long-Term Course, Prognosis, Follow-Up, and Research Priorities - [6]
Cambras T, Domingo JC, Sanmartín-Sentañes R et al.. “Association between light exposure patterns and multidimensional health outcomes in individuals with myalgic encephalomyelitis/chronic fatigue syndrome: findings from an observational cross-sectional cohort study.” Journal of translational medicine (2026). PMID: 42399727 ↗
Journal Article, Observational Study, Research Support, Non-U.S. Gov'tCited in: ME/CFS: Definition, Nomenclature, and the Core Clinical Concept, The ME/CFS Phenotype: PEM, Sleep, Cognition, Autonomic Symptoms, and Pain, Symptom-Directed Treatment: Sleep, Pain, Orthostatic Intolerance, and Comorbid Symptoms, Coexisting Conditions and Coordinated Family-Medicine Care, Long-Term Course, Prognosis, Follow-Up, and Research Priorities - [7]
Xu H, Li Q, Luo Y et al.. “Neurovascular and synaptic milieu of brain-resident cells in cognitive dysfunction of myalgic encephalomyelitis/chronic fatigue syndrome.” Journal of translational medicine (2026). PMID: 42015171 ↗
Journal Article, ReviewCited in: ME/CFS: Definition, Nomenclature, and the Core Clinical Concept, The ME/CFS Phenotype: PEM, Sleep, Cognition, Autonomic Symptoms, and Pain - [8]
Saurel M, Fornasieri I, Del Sordo GC et al.. “Sleep in myalgic encephalomyelitis/chronic fatigue syndrome shows marked night-to-night fluctuation under free-living conditions-results from a matched case-control study.” Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine (2026). PMID: 42129014 ↗
Journal ArticleCited in: ME/CFS: Definition, Nomenclature, and the Core Clinical Concept, The ME/CFS Phenotype: PEM, Sleep, Cognition, Autonomic Symptoms, and Pain, Excluding Mimics: Differential Diagnosis and Targeted Primary-Care Investigations, Symptom-Directed Treatment: Sleep, Pain, Orthostatic Intolerance, and Comorbid Symptoms, Coexisting Conditions and Coordinated Family-Medicine Care, Long-Term Course, Prognosis, Follow-Up, and Research Priorities - [9]
Brown M, Vernon SD, Indart AC et al.. “Gastrointestinal symptoms correlate with core clinical features and systemic inflammation in myalgic encephalomyelitis/chronic fatigue syndrome.” Journal of translational medicine (2026). PMID: 42321833 ↗
Journal Article, Research Support, N.I.H., ExtramuralCited in: ME/CFS: Definition, Nomenclature, and the Core Clinical Concept, The ME/CFS Phenotype: PEM, Sleep, Cognition, Autonomic Symptoms, and Pain, Coexisting Conditions and Coordinated Family-Medicine Care - [10]
Ghali A, Lavigne C, Ghali M et al.. “Post-Exertional Malaise in Post-COVID-19 Syndrome: A Shift in the Frequency Across Pandemic Phases.” Journal of clinical medicine (2026). PMID: 42074751 ↗
Journal ArticleCited in: ME/CFS: Definition, Nomenclature, and the Core Clinical Concept, Infectious Triggers, Predisposition, and Proposed Biology of ME/CFS, Who Develops ME/CFS: Epidemiology, Risk Context, and Health Inequities, The ME/CFS Phenotype: PEM, Sleep, Cognition, Autonomic Symptoms, and Pain, Crashes, Severe and Very Severe ME/CFS, Safety, and Escalation - [11]
Donath Q, Haegele M, Schindler D et al.. “Risk factors for severe post-COVID condition in children, adolescents, and young adults.” European journal of pediatrics (2026). PMID: 42082813 ↗
Journal Article, Observational StudyCited in: ME/CFS: Definition, Nomenclature, and the Core Clinical Concept, Who Develops ME/CFS: Epidemiology, Risk Context, and Health Inequities, Long-Term Course, Prognosis, Follow-Up, and Research Priorities - [12]
Jin H, An Y, Huang J et al.. “Pathophysiological mechanisms of post-exertional malaise: an integrative analysis based on the metabolism-immune-neuro interaction model.” Frontiers in immunology (2026). PMID: 42051540 ↗
Journal Article, Systematic ReviewCited in: ME/CFS: Definition, Nomenclature, and the Core Clinical Concept, Infectious Triggers, Predisposition, and Proposed Biology of ME/CFS, The ME/CFS Phenotype: PEM, Sleep, Cognition, Autonomic Symptoms, and Pain - [13]
Miwa K. “Disequilibrium, Rather than Postural Orthostatic Tachycardia Syndrome, Is the Primary Determinant of Orthostatic Intolerance in Patients with Long COVID.” Journal of clinical medicine (2026). PMID: 41899187 ↗
Journal ArticleCited in: ME/CFS: Definition, Nomenclature, and the Core Clinical Concept - [14]
Mihatsch L, Schartner L, de Luna JL et al.. “Handgrip strength in children, adolescents, and young adults with suspected myalgic encephalomyelitis/chronic fatigue syndrome.” Journal of translational medicine (2026). PMID: 42458481 ↗
Journal Article, Research Support, Non-U.S. Gov'tCited in: ME/CFS: Definition, Nomenclature, and the Core Clinical Concept, The ME/CFS Phenotype: PEM, Sleep, Cognition, Autonomic Symptoms, and Pain, Primary-Care Assessment: History, Examination, and Functional Baseline, Confirming ME/CFS: Case Definitions and Diagnostic Reasoning, Long-Term Course, Prognosis, Follow-Up, and Research Priorities - [15]
Mancini DM, Cook DB, Brunjes DL et al.. “Cardiopulmonary exercise test results do not change over two sequential days in patients with chronic fatigue syndrome.” Frontiers in physiology (2026). PMID: 42212259 ↗
Journal ArticleCited in: ME/CFS: Definition, Nomenclature, and the Core Clinical Concept, Infectious Triggers, Predisposition, and Proposed Biology of ME/CFS, The ME/CFS Phenotype: PEM, Sleep, Cognition, Autonomic Symptoms, and Pain, Excluding Mimics: Differential Diagnosis and Targeted Primary-Care Investigations, Severity, Functional Classification, and Outcome Measurement in ME/CFS, Crashes, Severe and Very Severe ME/CFS, Safety, and Escalation - [16]
Tack M, Gruber R, Betting L et al.. “Assessment and Incidence Determination of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Following a SARS-CoV-2 Infection in a Prospective Cohort of Hospital Employees.” Medicina (Kaunas, Lithuania) (2026). PMID: 41901562 ↗
Journal ArticleCited in: ME/CFS: Definition, Nomenclature, and the Core Clinical Concept, Infectious Triggers, Predisposition, and Proposed Biology of ME/CFS, Confirming ME/CFS: Case Definitions and Diagnostic Reasoning - [17]
Eaton-Fitch N, Marshall-Gradisnik S. “Australian registry reports poor health and wellbeing in people living with ME/CFS.” Journal of translational medicine (2026). PMID: 42443918 ↗
Journal ArticleCited in: ME/CFS: Definition, Nomenclature, and the Core Clinical Concept, Who Develops ME/CFS: Epidemiology, Risk Context, and Health Inequities, Severity, Functional Classification, and Outcome Measurement in ME/CFS, Crashes, Severe and Very Severe ME/CFS, Safety, and Escalation - [18]
Tomić S, Pastornački A, Drljača M et al.. “Long-Term Follow-Up of Women with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): A 16-Year Longitudinal Study.” Medicina (Kaunas, Lithuania) (2026). PMID: 42356126 ↗
Journal ArticleCited in: ME/CFS: Definition, Nomenclature, and the Core Clinical Concept, The ME/CFS Phenotype: PEM, Sleep, Cognition, Autonomic Symptoms, and Pain, Confirming ME/CFS: Case Definitions and Diagnostic Reasoning, Excluding Mimics: Differential Diagnosis and Targeted Primary-Care Investigations, Severity, Functional Classification, and Outcome Measurement in ME/CFS, Coexisting Conditions and Coordinated Family-Medicine Care, Long-Term Course, Prognosis, Follow-Up, and Research Priorities - [19]
Wirth KJ, Scheibenbogen C. “Imbalance of Excitatory and Inhibitory Neurotransmitter Systems in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.” International journal of molecular sciences (2026). PMID: 42123618 ↗
Journal Article, ReviewCited in: ME/CFS: Definition, Nomenclature, and the Core Clinical Concept, Infectious Triggers, Predisposition, and Proposed Biology of ME/CFS, The ME/CFS Phenotype: PEM, Sleep, Cognition, Autonomic Symptoms, and Pain, Crashes, Severe and Very Severe ME/CFS, Safety, and Escalation - [20]
Frank J, Nesterovitch N, Movva C et al.. “Toward a Molecular Reclassification of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Integrating Multi-Omics, Machine Learning, and Precision Medicine.” International journal of molecular sciences (2026). PMID: 42196410 ↗
Journal Article, ReviewCited in: ME/CFS: Definition, Nomenclature, and the Core Clinical Concept, Long-Term Course, Prognosis, Follow-Up, and Research Priorities - [21]
Blitshteyn S, Doherty TA, Steinman L. “Postural Orthostatic Tachycardia Syndrome, Myalgic Encephalomyelitis/Chronic Fatigue Syndrome and Long COVID as Neuroimmune Disorders.” ImmunoTargets and therapy (2026). PMID: 41859298 ↗
Journal Article, ReviewCited in: Infectious Triggers, Predisposition, and Proposed Biology of ME/CFS - [22]
Hu Z, Wang J, Ma S et al.. “Immune remodeling and metabolic reprogramming in chronic fatigue: insights into GPCR signaling and epigenetic regulation.” Frontiers in immunology (2026). PMID: 42220511 ↗
Journal Article, ReviewCited in: Infectious Triggers, Predisposition, and Proposed Biology of ME/CFS - [23]
Sardell JM, Das S, Pearson M et al.. “Identification of novel reproducible combinatorial genetic risk factors for myalgic encephalomyelitis in the DecodeME patient cohort and commonalities with long COVID.” Journal of translational medicine (2026). PMID: 42015188 ↗
Journal Article, Research Support, Non-U.S. Gov'tCited in: Infectious Triggers, Predisposition, and Proposed Biology of ME/CFS, Who Develops ME/CFS: Epidemiology, Risk Context, and Health Inequities - [24]
Jason LA, Furst J, Katz BZ. “Comparing ME/CFS following mononucleosis with Long COVID.” Chronic illness (2026). PMID: 41984971 ↗
Journal ArticleCited in: Infectious Triggers, Predisposition, and Proposed Biology of ME/CFS, Who Develops ME/CFS: Epidemiology, Risk Context, and Health Inequities, The ME/CFS Phenotype: PEM, Sleep, Cognition, Autonomic Symptoms, and Pain, Excluding Mimics: Differential Diagnosis and Targeted Primary-Care Investigations - [25]
Jason LA, Furst J, Worth R et al.. “Outcomes of ME/CFS following infectious mononucleosis: seven-year follow-up of a prospective study.” Frontiers in medicine (2026). PMID: 41836950 ↗
Journal ArticleCited in: Infectious Triggers, Predisposition, and Proposed Biology of ME/CFS, Confirming ME/CFS: Case Definitions and Diagnostic Reasoning, Crashes, Severe and Very Severe ME/CFS, Safety, and Escalation - [26]
Azcue N, Barranco C, Tijero-Merino B et al.. “Two-timepoint multidomain follow-up of post-COVID condition and ME/CFS: overlapping autonomic, small-fiber, and cognitive changes.” Journal of translational medicine (2026). PMID: 42286686 ↗
Journal Article, Research Support, Non-U.S. Gov'tCited in: Infectious Triggers, Predisposition, and Proposed Biology of ME/CFS, The ME/CFS Phenotype: PEM, Sleep, Cognition, Autonomic Symptoms, and Pain, Excluding Mimics: Differential Diagnosis and Targeted Primary-Care Investigations, Coexisting Conditions and Coordinated Family-Medicine Care, Long-Term Course, Prognosis, Follow-Up, and Research Priorities - [27]
Petrov S, Bozhkova M, Ivanovska M et al.. “Comprehensive Immunophenotyping of Monocytes and Dendritic Cells Suggests Distinct Pathophysiology in Chronic Fatigue Syndrome and Long COVID.” International journal of molecular sciences (2026). PMID: 42196466 ↗
Journal ArticleCited in: Infectious Triggers, Predisposition, and Proposed Biology of ME/CFS - [28]
Wallraven T, Günthner R, Lethen I et al.. “Microvascular remodeling and endothelial dysfunction across the post-COVID-19 spectrum: a prospective observational case-control study.” BMC medicine (2026). PMID: 42625188 ↗
Journal Article, Observational StudyCited in: Infectious Triggers, Predisposition, and Proposed Biology of ME/CFS - [29]
Kumar S, Veldhuis A, Yazdani F. “Higher-order brain processes, rather than early processing, underlie sensory problems in ME/CFS: evidence from ERPs.” Frontiers in medicine (2026). PMID: 42396162 ↗
Journal ArticleCited in: Infectious Triggers, Predisposition, and Proposed Biology of ME/CFS - [30]
Souma B, Elremaly W, Akoume MY et al.. “Irisin Signaling Resistance in Myalgic Encephalomyelitis: A Proposed Mechanistic Framework for Post-Exertional Malaise Involving the TSP-1-HSP90α-αvβ5 Axis.” International journal of molecular sciences (2026). PMID: 42278300 ↗
Journal ArticleCited in: Infectious Triggers, Predisposition, and Proposed Biology of ME/CFS - [31]
Omdal R, Lenning OB, Jonsson G et al.. “Persistent fatigue in long-COVID is not associated with peripheral inflammatory or cellular stress biomarkers: A cross-sectional controlled study.” Brain, behavior, & immunity - health (2026). PMID: 42004496 ↗
Journal ArticleCited in: Infectious Triggers, Predisposition, and Proposed Biology of ME/CFS - [32]
Habermann-Horstmeier L, Horstmeier LM. “Symptom clusters in ME/CFS reflect distinct neuroimmune and autonomic pathophysiological mechanisms: a translational model.” Journal of translational medicine (2026). PMID: 42050709 ↗
Journal Article, Research Support, Non-U.S. Gov'tCited in: Infectious Triggers, Predisposition, and Proposed Biology of ME/CFS, The ME/CFS Phenotype: PEM, Sleep, Cognition, Autonomic Symptoms, and Pain, Coexisting Conditions and Coordinated Family-Medicine Care, Crashes, Severe and Very Severe ME/CFS, Safety, and Escalation - [33]
McGrath SJ, Hillier CB, Dibble JJ et al.. “Incidence age is bimodal for myalgic encephalomyelitis/chronic fatigue syndrome, with higher severity burden for early onset disease.” Oxford open immunology (2026). PMID: 41983041 ↗
Journal ArticleCited in: Who Develops ME/CFS: Epidemiology, Risk Context, and Health Inequities, Severity, Functional Classification, and Outcome Measurement in ME/CFS, Crashes, Severe and Very Severe ME/CFS, Safety, and Escalation - [34]
Yuan Y, Wen L, Fu H et al.. “Distribution characteristics of chronic fatigue syndrome among secondary school students and its association with physical health: a case study in Shaanxi Province.” Frontiers in pediatrics (2026). PMID: 42519734 ↗
Journal ArticleCited in: Who Develops ME/CFS: Epidemiology, Risk Context, and Health Inequities - [35]
Bowden N, McLeod K, Anns F et al.. “Health, labour market, and social service outcomes for people with Myalgic Encephalomyelitis / Chronic Fatigue Syndrome on a health or disability related benefit: an Aotearoa | New Zealand nationwide cross-sectional study using the integrated data infrastructure.” BMC public health (2026). PMID: 42032509 ↗
Journal ArticleCited in: Who Develops ME/CFS: Epidemiology, Risk Context, and Health Inequities, Severity, Functional Classification, and Outcome Measurement in ME/CFS, Work, Education, Disability, Carer Support, and Access to Care, Long-Term Course, Prognosis, Follow-Up, and Research Priorities - [36]
Mao S, Wu L. “The role of disease history score in the association between depression history and current ME/CFS among US adults.” Frontiers in public health (2026). PMID: 42553043 ↗
Journal ArticleCited in: Who Develops ME/CFS: Epidemiology, Risk Context, and Health Inequities, Excluding Mimics: Differential Diagnosis and Targeted Primary-Care Investigations, Coexisting Conditions and Coordinated Family-Medicine Care - [37]
Habermann-Horstmeier L, Horstmeier LM. “Sex- and menopause-related differences in immune and gastrointestinal symptom architecture in ME/CFS: evidence from factor analysis and structural equation modeling.” Journal of translational medicine (2026). PMID: 42522006 ↗
Journal Article, Research Support, Non-U.S. Gov'tCited in: Who Develops ME/CFS: Epidemiology, Risk Context, and Health Inequities, The ME/CFS Phenotype: PEM, Sleep, Cognition, Autonomic Symptoms, and Pain, Coexisting Conditions and Coordinated Family-Medicine Care - [38]
Grach SL, Seltzer J, Mueller MR et al.. “Underuse of Pharmacologic Therapies for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Before Specialist Evaluation.” Annals of family medicine (2026). PMID: 42055743 ↗
Journal ArticleCited in: Who Develops ME/CFS: Epidemiology, Risk Context, and Health Inequities, Excluding Mimics: Differential Diagnosis and Targeted Primary-Care Investigations, Symptom-Directed Treatment: Sleep, Pain, Orthostatic Intolerance, and Comorbid Symptoms, Coexisting Conditions and Coordinated Family-Medicine Care - [39]
Seltzer J, Grach SL, Eggers SD et al.. “Improving Diagnostic Accuracy of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Through a Point-of-Care Clinical Algorithm.” International journal of environmental research and public health (2026). PMID: 42074399 ↗
Journal ArticleCited in: Who Develops ME/CFS: Epidemiology, Risk Context, and Health Inequities, Confirming ME/CFS: Case Definitions and Diagnostic Reasoning, Excluding Mimics: Differential Diagnosis and Targeted Primary-Care Investigations, Coexisting Conditions and Coordinated Family-Medicine Care - [40]
Kitselaar WM, Hartmann L, Evers AWM et al.. “Longitudinal association of mental-health problems with subsequent diagnosis of persistent somatic symptom disorders: A large-scale registry-based observational study in primary care.” General hospital psychiatry (2026). PMID: 42167072 ↗
Journal Article, Observational StudyCited in: Who Develops ME/CFS: Epidemiology, Risk Context, and Health Inequities, Long-Term Course, Prognosis, Follow-Up, and Research Priorities - [41]
Nematbakhsh S, Mohammadifard N, Riahi R et al.. “Prediction of post-COVID chronic fatigue syndrome using data mining and machine learning techniques in Isfahan COVID cohort study.” Journal of infection and public health (2026). PMID: 42000587 ↗
Journal ArticleCited in: Who Develops ME/CFS: Epidemiology, Risk Context, and Health Inequities - [42]
Arnaboldi PM, Becker J, Nath A et al.. “Designing studies for post-treatment Lyme disease and other infection-associated chronic illnesses.” Brain : a journal of neurology (2026). PMID: 42148664 ↗
Journal Article, ReviewCited in: Who Develops ME/CFS: Epidemiology, Risk Context, and Health Inequities, Confirming ME/CFS: Case Definitions and Diagnostic Reasoning, Excluding Mimics: Differential Diagnosis and Targeted Primary-Care Investigations, Long-Term Course, Prognosis, Follow-Up, and Research Priorities - [43]
Schieffer B. “Redefining pandemic resilience: a roadmap for post-infectious syndrome preparedness and health system transformation.” Frontiers in health services (2026). PMID: 42358486 ↗
Journal ArticleCited in: Who Develops ME/CFS: Epidemiology, Risk Context, and Health Inequities - [44]
Grønning K, Lysfjord LE, Røstad AKH. “Self-management support needs for individuals with Myalgic Encephalomyelitis and their next of kin - a qualitative study.” BMC health services research (2026). PMID: 42298601 ↗
Journal ArticleCited in: Who Develops ME/CFS: Epidemiology, Risk Context, and Health Inequities, Energy Management and Pacing: Protecting the Activity Envelope, Coexisting Conditions and Coordinated Family-Medicine Care, Long-Term Course, Prognosis, Follow-Up, and Research Priorities - [45]
Westermeier F, Pretorius E, Untersmayr E et al.. “A cardiometabolic perspective on post-exertional malaise in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and Long COVID.” Cardiovascular diabetology (2026). PMID: 42625219 ↗
EditorialCited in: The ME/CFS Phenotype: PEM, Sleep, Cognition, Autonomic Symptoms, and Pain, Excluding Mimics: Differential Diagnosis and Targeted Primary-Care Investigations, Crashes, Severe and Very Severe ME/CFS, Safety, and Escalation - [46]
Welch DC, Edwards CC, Broussard CA et al.. “Validation of the Wood Mental Fatigue Inventory in adolescents with myalgic encephalomyelitis/chronic fatigue syndrome.” Brain, behavior, & immunity - health (2026). PMID: 41953581 ↗
Journal ArticleCited in: The ME/CFS Phenotype: PEM, Sleep, Cognition, Autonomic Symptoms, and Pain, Severity, Functional Classification, and Outcome Measurement in ME/CFS, Long-Term Course, Prognosis, Follow-Up, and Research Priorities - [47]
Yamazaki T, Mancini DM, Blate M et al.. “Total blood volume and red blood cell volume are not associated with orthostatic intolerance in adults with myalgic encephalomyelitis/chronic fatigue syndrome.” Physiological reports (2026). PMID: 42717554 ↗
Journal ArticleCited in: The ME/CFS Phenotype: PEM, Sleep, Cognition, Autonomic Symptoms, and Pain, Excluding Mimics: Differential Diagnosis and Targeted Primary-Care Investigations, Coexisting Conditions and Coordinated Family-Medicine Care, Crashes, Severe and Very Severe ME/CFS, Safety, and Escalation - [48]
Sun H, Dang R, Li P et al.. “Facility-measured sleep electroencephalographic microstructures in long COVID.” Sleep (2026). PMID: 42017829 ↗
Journal ArticleCited in: The ME/CFS Phenotype: PEM, Sleep, Cognition, Autonomic Symptoms, and Pain, Excluding Mimics: Differential Diagnosis and Targeted Primary-Care Investigations, Coexisting Conditions and Coordinated Family-Medicine Care - [49]
Montoya JG, Dowell TG, Mooney AE et al.. “Caring for the Patient with Severe or Very Severe Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.” Healthcare (Basel, Switzerland) (2021). PMID: 34683011 ↗
Journal ArticleCited in: Primary-Care Assessment: History, Examination, and Functional Baseline, Symptom-Directed Treatment: Sleep, Pain, Orthostatic Intolerance, and Comorbid Symptoms, Work, Education, Disability, Carer Support, and Access to Care - [50]
Unger ER, Lin JS, Chen Y et al.. “Heterogeneity in Measures of Illness among Patients with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Is Not Explained by Clinical Practice: A Study in Seven U.S. Specialty Clinics.” Journal of clinical medicine (2024). PMID: 38592199 ↗
Journal ArticleCited in: Primary-Care Assessment: History, Examination, and Functional Baseline - [51]
Yang M, Keller S, Rafiee P et al.. “Psychometric evaluation of the PROMIS® physical function short form 12a for use by adults with myalgic encephalomyelitis/chronic fatigue syndrome.” Health and quality of life outcomes (2025). PMID: 41053836 ↗
Journal ArticleCited in: Primary-Care Assessment: History, Examination, and Functional Baseline - [52]
Eyskens JB, Illegems J, De Nil L et al.. “Assessing chronic fatigue syndrome: Self-reported physical functioning and correlations with physical testing.” Journal of bodywork and movement therapies (2019). PMID: 31563377 ↗
Journal ArticleCited in: Primary-Care Assessment: History, Examination, and Functional Baseline - [53]
Jason L, Brown M, Evans M et al.. “Measuring substantial reductions in functioning in patients with chronic fatigue syndrome.” Disability and rehabilitation (2010). PMID: 20617920 ↗
Comparative Study, Journal Article, Research Support, N.I.H., ExtramuralCited in: Primary-Care Assessment: History, Examination, and Functional Baseline - [54]
Evering RM, Tönis TM, Vollenbroek-Hutten MM. “Deviations in daily physical activity patterns in patients with the chronic fatigue syndrome: a case control study.” Journal of psychosomatic research (2011). PMID: 21843746 ↗
Journal ArticleCited in: Primary-Care Assessment: History, Examination, and Functional Baseline - [55]
Rahman K, Burton A, Galbraith S et al.. “Sleep-wake behavior in chronic fatigue syndrome.” Sleep (2011). PMID: 21532961 ↗
Journal Article, Research Support, Non-U.S. Gov'tCited in: Primary-Care Assessment: History, Examination, and Functional Baseline - [56]
Davenport TE, Stevens SR, Stevens J et al.. “Properties of measurements obtained during cardiopulmonary exercise testing in individuals with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.” Work (Reading, Mass.) (2020). PMID: 32568145 ↗
Journal ArticleCited in: Primary-Care Assessment: History, Examination, and Functional Baseline - [57]
Nijs J, Aelbrecht S, Meeus M et al.. “Tired of being inactive: a systematic literature review of physical activity, physiological exercise capacity and muscle strength in patients with chronic fatigue syndrome.” Disability and rehabilitation (2010). PMID: 21166613 ↗
Journal Article, Research Support, Non-U.S. Gov't, Systematic ReviewCited in: Primary-Care Assessment: History, Examination, and Functional Baseline - [58]
Strand EB, Mengshoel AM, Sandvik L et al.. “Pain is associated with reduced quality of life and functional status in patients with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.” Scandinavian journal of pain (2019). PMID: 30325738 ↗
Journal Article, Research Support, Non-U.S. Gov'tCited in: Primary-Care Assessment: History, Examination, and Functional Baseline - [59]
Goedendorp MM, Knoop H, Schippers GM et al.. “The lifestyle of patients with chronic fatigue syndrome and the effect on fatigue and functional impairments.” Journal of human nutrition and dietetics : the official journal of the British Dietetic Association (2009). PMID: 19226353 ↗
Journal ArticleCited in: Primary-Care Assessment: History, Examination, and Functional Baseline - [60]
Priebe S, Fakhoury WK, Henningsen P. “Functional incapacity and physical and psychological symptoms: how they interconnect in chronic fatigue syndrome.” Psychopathology (2008). PMID: 18765959 ↗
Journal ArticleCited in: Primary-Care Assessment: History, Examination, and Functional Baseline - [61]
Band R, Barrowclough C, Caldwell K et al.. “Activity patterns in response to symptoms in patients being treated for chronic fatigue syndrome: An experience sampling methodology study.” Health psychology : official journal of the Division of Health Psychology, American Psychological Association (2016). PMID: 27819461 ↗
Journal ArticleCited in: Primary-Care Assessment: History, Examination, and Functional Baseline - [62]
Antcliff D, Campbell M, Woby S et al.. “Activity Pacing is Associated With Better and Worse Symptoms for Patients With Long-term Conditions.” The Clinical journal of pain (2017). PMID: 27322396 ↗
Journal Article, Research Support, Non-U.S. Gov'tCited in: Primary-Care Assessment: History, Examination, and Functional Baseline - [63]
Yang M, Keller S, Lin JS. “Psychometric properties of the PROMIS® Fatigue Short Form 7a among adults with myalgic encephalomyelitis/chronic fatigue syndrome.” Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation (2019). PMID: 31506915 ↗
Evaluation Study, Journal ArticleCited in: Primary-Care Assessment: History, Examination, and Functional Baseline - [64]
Popkirov S. “Variation in Repeated Handgrip Strength Testing Indicates Submaximal Force Production in Patients With Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.” European journal of neurology (2025). PMID: 40923211 ↗
Journal ArticleCited in: Primary-Care Assessment: History, Examination, and Functional Baseline - [65]
Durham J, McDonald C, Hutchinson L et al.. “Painful temporomandibular disorders are common in patients with postural orthostatic tachycardia syndrome and impact significantly upon quality of life.” Journal of oral & facial pain and headache (2015). PMID: 25905533 ↗
Journal Article, Research Support, Non-U.S. Gov'tCited in: Primary-Care Assessment: History, Examination, and Functional Baseline - [66]
Rowe PC, Marden CL, Flaherty MAK et al.. “Two-Year Follow-Up of Impaired Range of Motion in Chronic Fatigue Syndrome.” The Journal of pediatrics (2018). PMID: 29866593 ↗
Journal Article, Research Support, Non-U.S. Gov'tCited in: Primary-Care Assessment: History, Examination, and Functional Baseline - [67]
Friedberg F, Napoli A, Coronel J et al.. “Chronic fatigue self-management in primary care: a randomized trial.” Psychosomatic medicine (2013). PMID: 23922399 ↗
Journal Article, Randomized Controlled Trial, Research Support, N.I.H., ExtramuralCited in: Primary-Care Assessment: History, Examination, and Functional Baseline - [68]
Fan J, Jiao J, Chang HQ et al.. “Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS): diagnosis and management.” Journal of translational medicine (2025). PMID: 41366804 ↗
Journal Article, ReviewCited in: Confirming ME/CFS: Case Definitions and Diagnostic Reasoning, Energy Management and Pacing: Protecting the Activity Envelope - [69]
Xu Q, Zhao M, Wang Q et al.. “Chronic fatigue syndrome: From etiology and mechanism to diagnosis and treatment.” Journal of psychiatric research (2026). PMID: 41707618 ↗
Journal Article, Review, Research Support, Non-U.S. Gov'tCited in: Confirming ME/CFS: Case Definitions and Diagnostic Reasoning - [70]
Lu J, Sun W, Li S et al.. “Assessment of symptoms in myalgic encephalomyelitis/chronic fatigue syndrome: a comparative study of existing scales.” Frontiers in neurology (2025). PMID: 41341517 ↗
Journal Article, ReviewCited in: Confirming ME/CFS: Case Definitions and Diagnostic Reasoning - [71]
Kujawski S, Tabisz H, Morten KJ et al.. “Diagnosis of chronic fatigue syndrome using beat-to-beat autonomic measurements.” Journal of translational medicine (2025). PMID: 41437251 ↗
Journal ArticleCited in: Confirming ME/CFS: Case Definitions and Diagnostic Reasoning - [72]
Ivanovska M, Homadi MS, Angelova G et al.. “Differential Characteristics and Comparison Between Long-COVID Syndrome and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS).” Biomedicines (2025). PMID: 41301889 ↗
Journal Article, ReviewCited in: Confirming ME/CFS: Case Definitions and Diagnostic Reasoning - [73]
Murovska M, Krumina A, Araja D et al.. “Myalgic encephalomyelitis/chronic fatigue syndrome and fibromyalgia - overlap, differences, and emerging insights.” Journal of translational medicine (2026). PMID: 41715182 ↗
Journal Article, Review, Research Support, Non-U.S. Gov'tCited in: Confirming ME/CFS: Case Definitions and Diagnostic Reasoning - [74]
Milovanovic B, Markovic N, Petrovic M et al.. “The Relationship Between Hemodynamic Responses During Head-Up Tilt Testing and Parameters of Infection in Post-COVID Syndrome, Chronic Fatigue Syndrome, and Late-Stage Lyme Disease.” Viruses (2025). PMID: 41305452 ↗
Journal ArticleCited in: Confirming ME/CFS: Case Definitions and Diagnostic Reasoning - [75]
Saini U, Aggen SH, Oldehinkel AJ et al.. “Disentangling comorbidity: symptom dimensions of internalizing and functional disorders in a large general population sample.” BMC psychiatry (2026). PMID: 41546021 ↗
Journal ArticleCited in: Confirming ME/CFS: Case Definitions and Diagnostic Reasoning - [76]
Fricke C, Deibert P, Maier P et al.. “ACHTSAM study protocol: outreach diagnostics and assessment of tolerability in severe ME/CFS-a pilot study.” BMJ open (2026). PMID: 41791789 ↗
Journal Article, Observational StudyCited in: Confirming ME/CFS: Case Definitions and Diagnostic Reasoning, Crashes, Severe and Very Severe ME/CFS, Safety, and Escalation - [77]
Weidmann C, Grabbe A, Eberhartinger M et al.. “Novel activity and participation scales for children, adolescents, and young adults with postacute infection and vaccination syndromes and/or ME/CFS.” European journal of pediatrics (2026). PMID: 42249231 ↗
Journal Article, Validation StudyCited in: Confirming ME/CFS: Case Definitions and Diagnostic Reasoning, Crashes, Severe and Very Severe ME/CFS, Safety, and Escalation - [78]
Oosterman JM, van der Schaaf M, de Kleijn WPE et al.. “The association of fatigue and pain with cognitive test performance in patients with myalgic encephalomyelitis/chronic fatigue syndrome.” Journal of psychosomatic research (2025). PMID: 41101039 ↗
Journal Article, Research Support, Non-U.S. Gov'tCited in: Confirming ME/CFS: Case Definitions and Diagnostic Reasoning - [79]
Tattan M, Hanssen DJC, Rosmalen JGM. “Who receives a diagnostic label for fibromyalgia, chronic fatigue syndrome, and irritable bowel syndrome? A study in the lifelines cohort.” Journal of psychosomatic research (2026). PMID: 41812541 ↗
Journal ArticleCited in: Confirming ME/CFS: Case Definitions and Diagnostic Reasoning - [80]
Hunter E, Alshaker H, Bundock O et al.. “Development and validation of blood-based diagnostic biomarkers for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) using EpiSwitch® 3-dimensional genomic regulatory immuno-genetic profiling.” Journal of translational medicine (2025). PMID: 41057909 ↗
Journal Article, Validation Study, Research Support, Non-U.S. Gov'tCited in: Confirming ME/CFS: Case Definitions and Diagnostic Reasoning - [81]
Eguchi A, Kuratsune H, Nakatomi Y et al.. “Circulating extracellular vesicles-microRNAs as potential biomarkers for the identification of ME/CFS: differentiating fatigue-related conditions.” Journal of translational medicine (2026). PMID: 42533331 ↗
Journal Article, Research Support, Non-U.S. Gov'tCited in: Excluding Mimics: Differential Diagnosis and Targeted Primary-Care Investigations - [82]
Woo TW, Choi YJ, Kim JY et al.. “Neuroendocrine signature of ME/CFS: Meta-analytic evidence for bioactive cortisol deficit and exaggerated feedback sensitivity.” Molecular psychiatry (2026). PMID: 42026257 ↗
Journal Article, Meta-Analysis, Systematic ReviewCited in: Excluding Mimics: Differential Diagnosis and Targeted Primary-Care Investigations - [83]
Saini U, Wanders R, Oldehinkel AJ et al.. “Data-driven subtypes of internalizing and functional somatic symptoms: A hybrid mixture modeling approach.” General hospital psychiatry (2026). PMID: 42594760 ↗
Journal ArticleCited in: Excluding Mimics: Differential Diagnosis and Targeted Primary-Care Investigations, Coexisting Conditions and Coordinated Family-Medicine Care - [84]
Ruhrländer J, Schieffer E, Schieffer B. “Regulatory Cycles of Orexin and Glucagon-Like Peptide-1 in Post-Viral Syndromes.” Endocrine reviews (2026). PMID: 42037238 ↗
Journal ArticleCited in: Excluding Mimics: Differential Diagnosis and Targeted Primary-Care Investigations - [85]
Niederman CN. “A Perspective on Observation as Intervention in Chronic Diagnostic Complexity.” Journal of patient experience (2026). PMID: 42137851 ↗
Journal ArticleCited in: Excluding Mimics: Differential Diagnosis and Targeted Primary-Care Investigations - [86]
Wendt K, Schieck M, Gille C et al.. “Biomarkers of post-acute infection syndrome: a systematic literature review.” Frontiers in immunology (2026). PMID: 42454043 ↗
Journal Article, Systematic ReviewCited in: Excluding Mimics: Differential Diagnosis and Targeted Primary-Care Investigations, Long-Term Course, Prognosis, Follow-Up, and Research Priorities - [87]
Heidarifard M, Moezzi A, Dallaire F et al.. “Raman Spectroscopy Combined with Machine Learning Reveals Myalgic Encephalomyelitis-Associated Biomolecular Signatures at Rest and After Standardized Stress.” International journal of molecular sciences (2026). PMID: 42278463 ↗
Journal ArticleCited in: Severity, Functional Classification, and Outcome Measurement in ME/CFS - [88]
Ribeiro V, Azevedo P, Westermeier F et al.. “A Short-Term Pacing Intervention in People with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Pilot Study in Portugal.” Medicina (Kaunas, Lithuania) (2026). PMID: 41752730 ↗
Journal ArticleCited in: Severity, Functional Classification, and Outcome Measurement in ME/CFS - [89]
Goudsmit EM, Nijs J, Jason LA et al.. “Pacing as a strategy to improve energy management in myalgic encephalomyelitis/chronic fatigue syndrome: a consensus document.” Disability and rehabilitation (2011). PMID: 22181560 ↗
Journal Article, Review, Consensus StatementCited in: Energy Management and Pacing: Protecting the Activity Envelope - [90]
Kingdon C, Lowe A, Shepherd C et al.. “What Primary Care Practitioners Need to Know about the New NICE Guideline for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome in Adults.” Healthcare (Basel, Switzerland) (2022). PMID: 36553962 ↗
Journal ArticleCited in: Energy Management and Pacing: Protecting the Activity Envelope, Symptom-Directed Treatment: Sleep, Pain, Orthostatic Intolerance, and Comorbid Symptoms - [91]
Hoffmann K, Hainzl A, Stingl M et al.. “[Interdisciplinary, collaborative D-A-CH (Germany, Austria and Switzerland) consensus statement concerning the diagnostic and treatment of myalgic encephalomyelitis/chronic fatigue syndrome].” Wiener klinische Wochenschrift (2024). PMID: 38743348 ↗
Journal Article, Consensus Statement, English AbstractCited in: Energy Management and Pacing: Protecting the Activity Envelope, Symptom-Directed Treatment: Sleep, Pain, Orthostatic Intolerance, and Comorbid Symptoms - [92]
Cooper C, Papadopoulos K. “Evaluating pacing therapy (PT) versus graded exercise therapy (GET) for improving fatigue, pain, and quality of life in adults with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS): A systematic review.” Journal of bodywork and movement therapies (2025). PMID: 40954597 ↗
Journal Article, Systematic ReviewCited in: Energy Management and Pacing: Protecting the Activity Envelope - [93]
Pinxsterhuis I, Nordstokkå K, Jakobsen FA. “Theoretical foundation of the Activity Calculator - a method for fatigue management.” Scandinavian journal of occupational therapy (2025). PMID: 41474036 ↗
Journal ArticleCited in: Energy Management and Pacing: Protecting the Activity Envelope - [94]
Thornton EJ, Hayes LD, Goodwin DS et al.. “Managing Energy, and Shaping Care: Insights from Adults with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Through Co-Production Workshops.” The American journal of medicine (2025). PMID: 39961545 ↗
Journal ArticleCited in: Energy Management and Pacing: Protecting the Activity Envelope, Symptom-Directed Treatment: Sleep, Pain, Orthostatic Intolerance, and Comorbid Symptoms - [95]
Sanal-Hayes NEM, Hayes LD, Mclaughlin M et al.. “Pacing and energy management with digital tools for conditions with chronic fatigue: What we know so far in ME/CFS and Long COVID.” PLOS digital health (2026). PMID: 42507687 ↗
Journal ArticleCited in: Energy Management and Pacing: Protecting the Activity Envelope, Symptom-Directed Treatment: Sleep, Pain, Orthostatic Intolerance, and Comorbid Symptoms, Coexisting Conditions and Coordinated Family-Medicine Care - [96]
Balke M, Garbsch R, Cormann J et al.. “Design and validation of an energy level diary for fatigue management in patients with post-COVID syndrome.” Frontiers in rehabilitation sciences (2025). PMID: 40761505 ↗
Journal ArticleCited in: Energy Management and Pacing: Protecting the Activity Envelope - [97]
Barr J, Marsden L, Dassanayake T et al.. “Testing a Personalised Dysautonomia Management Protocol in Patients with Orthostatic Intolerance and a Diagnosis of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome or Long COVID.” Journal of clinical medicine (2026). PMID: 41976810 ↗
Journal ArticleCited in: Energy Management and Pacing: Protecting the Activity Envelope, Symptom-Directed Treatment: Sleep, Pain, Orthostatic Intolerance, and Comorbid Symptoms, Crashes, Severe and Very Severe ME/CFS, Safety, and Escalation, Long-Term Course, Prognosis, Follow-Up, and Research Priorities - [98]
Bateman L, Bested AC, Bonilla HF et al.. “Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Essentials of Diagnosis and Management.” Mayo Clinic proceedings (2021). PMID: 34454716 ↗
Journal Article, ReviewCited in: Energy Management and Pacing: Protecting the Activity Envelope, Symptom-Directed Treatment: Sleep, Pain, Orthostatic Intolerance, and Comorbid Symptoms - [99]
Vink M, Vink-Niese A. “The Updated NICE Guidance Exposed the Serious Flaws in CBT and Graded Exercise Therapy Trials for ME/CFS.” Healthcare (Basel, Switzerland) (2022). PMID: 35628033 ↗
Journal Article, ReviewCited in: Energy Management and Pacing: Protecting the Activity Envelope, Symptom-Directed Treatment: Sleep, Pain, Orthostatic Intolerance, and Comorbid Symptoms - [100]
Brown SI. “Graded exercise therapy for ME/CFS: finding consensus between the royal colleges, patients, and researchers.” BMJ (Clinical research ed.) (2021). PMID: 34880053 ↗
LetterCited in: Energy Management and Pacing: Protecting the Activity Envelope - [101]
Décary S, Gaboury I, Poirier S et al.. “Humility and Acceptance: Working Within Our Limits With Long COVID and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.” The Journal of orthopaedic and sports physical therapy (2021). PMID: 33930983 ↗
EditorialCited in: Energy Management and Pacing: Protecting the Activity Envelope - [102]
Gladwell PW, Pheby D, Rodriguez T et al.. “Use of an online survey to explore positive and negative outcomes of rehabilitation for people with CFS/ME.” Disability and rehabilitation (2013). PMID: 23735013 ↗
Journal ArticleCited in: Energy Management and Pacing: Protecting the Activity Envelope - [103]
Zhao L, Gou B, Zhang M. “The efficacy of exercise in patients with myalgic encephalomyelitis/chronic fatigue syndrome: A systematic review and meta-analysis.” Journal of psychosomatic research (2026). PMID: 42000527 ↗
Journal Article, Systematic Review, Meta-Analysis, Research Support, Non-U.S. Gov'tCited in: Energy Management and Pacing: Protecting the Activity Envelope, Symptom-Directed Treatment: Sleep, Pain, Orthostatic Intolerance, and Comorbid Symptoms - [104]
Oka T, Lkhagvasuren B, Yamada Y. “Effects of recumbent isometric yoga on the daily functioning level of patients with myalgic encephalomyelitis/chronic fatigue syndrome: a randomized, controlled trial.” BioPsychoSocial medicine (2025). PMID: 41074089 ↗
Journal ArticleCited in: Energy Management and Pacing: Protecting the Activity Envelope - [105]
Barry PW, Kelley K, Tan T et al.. “NICE guideline on ME/CFS: robust advice based on a thorough review of the evidence.” Journal of neurology, neurosurgery, and psychiatry (2024). PMID: 38418217 ↗
Journal Article, ReviewCited in: Symptom-Directed Treatment: Sleep, Pain, Orthostatic Intolerance, and Comorbid Symptoms - [106]
Nacul L, Authier FJ, Scheibenbogen C et al.. “European Network on Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (EUROMENE): Expert Consensus on the Diagnosis, Service Provision, and Care of People with ME/CFS in Europe.” Medicina (Kaunas, Lithuania) (2021). PMID: 34069603 ↗
Journal Article, Consensus StatementCited in: Symptom-Directed Treatment: Sleep, Pain, Orthostatic Intolerance, and Comorbid Symptoms - [107]
Schiweck N, Langer K, Maier A et al.. “Systematic literature review: treatment of postural orthostatic tachycardia syndrome (POTS).” Clinical autonomic research : official journal of the Clinical Autonomic Research Society (2025). PMID: 41225175 ↗
Journal Article, Systematic ReviewCited in: Symptom-Directed Treatment: Sleep, Pain, Orthostatic Intolerance, and Comorbid Symptoms - [108]
Dorczok MC, Mossaheb N, Mittmann G et al.. “Use and Perceived Helpfulness of Different Intervention Strategies in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome and Depression.” Journal of clinical medicine (2026). PMID: 41598786 ↗
Journal ArticleCited in: Symptom-Directed Treatment: Sleep, Pain, Orthostatic Intolerance, and Comorbid Symptoms - [109]
Deumer US, Varesi A, Floris V et al.. “Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): An Overview.” Journal of clinical medicine (2021). PMID: 34682909 ↗
Journal Article, ReviewCited in: Symptom-Directed Treatment: Sleep, Pain, Orthostatic Intolerance, and Comorbid Symptoms - [110]
Grande T, Grande B, Gerner P et al.. “The Role of Psychotherapy in the Care of Patients with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.” Medicina (Kaunas, Lithuania) (2023). PMID: 37109676 ↗
Journal ArticleCited in: Symptom-Directed Treatment: Sleep, Pain, Orthostatic Intolerance, and Comorbid Symptoms - [111]
Rajabi N, Ramdass PVAK. “Association between myalgic encephalomyelitis/chronic fatigue syndrome and irritable bowel syndrome: a systematic review and meta-analysis.” Frontiers in medicine (2026). PMID: 42577233 ↗
Journal Article, Systematic ReviewCited in: Coexisting Conditions and Coordinated Family-Medicine Care - [112]
Chinnappan B, Kempuraj D, Aenlle KK et al.. “Elevated serum levels of interleukin-11 and matrix metalloproteinase-9 in myalgic encephalomyelitis/chronic fatigue syndrome.” Frontiers in immunology (2026). PMID: 42327760 ↗
Journal ArticleCited in: Coexisting Conditions and Coordinated Family-Medicine Care - [113]
Tyson SF, Fleming R. “Development and Content Validity of the Clinical Needs Assessment for Myalgic Encephalomyelitis (CNAME).” Health expectations : an international journal of public participation in health care and health policy (2026). PMID: 42649108 ↗
Journal Article, Validation StudyCited in: Coexisting Conditions and Coordinated Family-Medicine Care - [114]
Belton S, Goss H, Whyte E et al.. “'I Want Everyone to Have It, and Everyone to Be on It': A Feasibility Study of the Transforming Long Covid Intervention.” Health expectations : an international journal of public participation in health care and health policy (2026). PMID: 42076812 ↗
Evaluation Study, Journal ArticleCited in: Coexisting Conditions and Coordinated Family-Medicine Care - [115]
Vink M, Vink-Niese A. “An Overview of Severe Myalgic Encephalomyelitis.” Journal of clinical medicine (2026). PMID: 41598742 ↗
Journal Article, ReviewCited in: Crashes, Severe and Very Severe ME/CFS, Safety, and Escalation - [116]
Wirth KJ, Steinacker JM. “The potential causes of myasthenia and fasciculations in severely ill ME/CFS patients: the role of disturbed electrophysiology.” Frontiers in physiology (2026). PMID: 41705124 ↗
Journal ArticleCited in: Crashes, Severe and Very Severe ME/CFS, Safety, and Escalation - [117]
Steinkirchner FM, Kaufmann CK, Kraus RF et al.. “Perioperative outcomes in patients with myalgic encephalomyelitis/chronic fatigue syndrome undergoing general anesthesia: a retrospective matched-pair study.” BMC anesthesiology (2026). PMID: 42464211 ↗
Journal ArticleCited in: Crashes, Severe and Very Severe ME/CFS, Safety, and Escalation - [118]
Iskander JK, Haridopolos S. “Making Invisible Illnesses Visible: Recognizing and Responding to Infection-Associated Chronic Conditions.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2026). PMID: 41967005 ↗
Case Reports, Journal Article, Review, Research Support, N.I.H., ExtramuralCited in: Crashes, Severe and Very Severe ME/CFS, Safety, and Escalation - [119]
Colgan DD, Buttolph L, Grow T et al.. “Designing Nutrition Studies for Long COVID and Related Infection-Associated Chronic Illness: Qualitative Insights From a Patient-Reported Evaluation of Ketogenic Metabolic Therapy.” Journal of patient experience (2026). PMID: 41993604 ↗
Journal ArticleCited in: Crashes, Severe and Very Severe ME/CFS, Safety, and Escalation - [120]
Dooms Y, Qiu L, Coppieters I et al.. “Multimodal approach to identify neuropsychophysiological subgroups in myalgic encephalomyelitis/chronic fatigue syndrome and their relevance for rehabilitation: protocol for a mechanistic cross-sectional and longitudinal study.” Brain, behavior, & immunity - health (2026). PMID: 42472232 ↗
Journal ArticleCited in: Crashes, Severe and Very Severe ME/CFS, Safety, and Escalation, Long-Term Course, Prognosis, Follow-Up, and Research Priorities - [121]
Nemat-Gorgani M, Jensen MA, Davis RW. “Glymphatic System Dysregulation as a Key Contributor to Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.” International journal of molecular sciences (2025). PMID: 41373677 ↗
Journal Article, ReviewCited in: Crashes, Severe and Very Severe ME/CFS, Safety, and Escalation - [122]
Podell R, Dimmock ME, Comerford BB. “Documenting disability in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS).” Work (Reading, Mass.) (2020). PMID: 32568153 ↗
Journal ArticleCited in: Work, Education, Disability, Carer Support, and Access to Care - [123]
Chu L, Fuentes LR, Marshall OM et al.. “Environmental accommodations for university students affected by Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS).” Work (Reading, Mass.) (2020). PMID: 32568151 ↗
Journal ArticleCited in: Work, Education, Disability, Carer Support, and Access to Care - [124]
Similä WA, Rø TB, Nøst TH. “Experiences Among School Personnel and School Nurses on Educational Adaptations for Students With CFS/ME: A Qualitative Interview Study.” Frontiers in pediatrics (2021). PMID: 34858906 ↗
Journal ArticleCited in: Work, Education, Disability, Carer Support, and Access to Care - [125]
Similä WA, Nøst TH, Helland IB et al.. “Factors related to educational adaptations and social life at school experienced by young people with CFS/ME: a qualitative study.” BMJ open (2021). PMID: 34794992 ↗
Journal Article, Research Support, Non-U.S. Gov'tCited in: Work, Education, Disability, Carer Support, and Access to Care - [126]
Newton FR. “The Impact of Severe ME/CFS on Student Learning and K-12 Educational Limitations.” Healthcare (Basel, Switzerland) (2021). PMID: 34070286 ↗
Journal Article, ReviewCited in: Work, Education, Disability, Carer Support, and Access to Care - [127]
Baken DM, Ross KJ, Hodges LD et al.. “Experiences of carers of youth, adult children and spouses with ME/CFS.” Chronic illness (2022). PMID: 36259126 ↗
Journal ArticleCited in: Work, Education, Disability, Carer Support, and Access to Care - [128]
Brigden A, Shaw A, Barnes R et al.. “"The child's got a complete circle around him". The care of younger children (5-11 years) with CFS/ME. A qualitative study comparing families', teachers' and clinicians' perspectives'.” Health & social care in the community (2020). PMID: 32519359 ↗
Journal Article, Research Support, Non-U.S. Gov'tCited in: Work, Education, Disability, Carer Support, and Access to Care - [129]
Haghshenas M, Steinsbekk A, Landmark T et al.. “Information exchange or discussion? A qualitative study on cross-sectoral collaboration between social security service and healthcare service for patients with chronic fatigue.” BMC health services research (2025). PMID: 41366432 ↗
Journal ArticleCited in: Work, Education, Disability, Carer Support, and Access to Care - [130]
Hussein S, Eiriksson L, MacQuarrie M et al.. “Healthcare system barriers impacting the care of Canadians with myalgic encephalomyelitis: A scoping review.” Journal of evaluation in clinical practice (2024). PMID: 39031904 ↗
Journal Article, Scoping Review, Research Support, Non-U.S. Gov'tCited in: Work, Education, Disability, Carer Support, and Access to Care - [131]
Sommerfelt K, Schei T, Angelsen A. “Severe and Very Severe Myalgic Encephalopathy/Chronic Fatigue Syndrome ME/CFS in Norway: Symptom Burden and Access to Care.” Journal of clinical medicine (2023). PMID: 36836022 ↗
Journal ArticleCited in: Work, Education, Disability, Carer Support, and Access to Care - [132]
Bolton MJ, Chew-Graham CA, van Marwijk H. “Under-Served Groups and Myalgic Encephalomyelitis Research Workshop; Multiple Barriers to Effective Healthcare, Research and Public Participation.” Health expectations : an international journal of public participation in health care and health policy (2025). PMID: 40094174 ↗
Journal ArticleCited in: Work, Education, Disability, Carer Support, and Access to Care - [133]
Melby L, Nair RD. “'We have no services for you… so you have to make the best out of it': A qualitative study of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome patients' dissatisfaction with healthcare services.” Health expectations : an international journal of public participation in health care and health policy (2023). PMID: 37905602 ↗
Journal Article, Research Support, Non-U.S. Gov'tCited in: Work, Education, Disability, Carer Support, and Access to Care - [134]
Sommerfelt K, Schei T, Seton KA et al.. “Assessing Functional Capacity in Myalgic Encephalopathy/Chronic Fatigue Syndrome: A Patient-Informed Questionnaire.” Journal of clinical medicine (2024). PMID: 38930014 ↗
Journal ArticleCited in: Work, Education, Disability, Carer Support, and Access to Care - [135]
Bileviciute-Ljungar I, Schult ML, Borg K et al.. “Preliminary ICF core set for patients with myalgic encephalomyelitis/chronic fatigue syndrome in rehabilitation medicine.” Journal of rehabilitation medicine (2020). PMID: 32488281 ↗
Journal ArticleCited in: Work, Education, Disability, Carer Support, and Access to Care - [136]
Conroy K, Bhatia S, Islam M et al.. “Homebound versus Bedridden Status among Those with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.” Healthcare (Basel, Switzerland) (2021). PMID: 33498489 ↗
Journal ArticleCited in: Work, Education, Disability, Carer Support, and Access to Care - [137]
Kingdon C, Giotas D, Nacul L et al.. “Health Care Responsibility and Compassion-Visiting the Housebound Patient Severely Affected by ME/CFS.” Healthcare (Basel, Switzerland) (2020). PMID: 32635535 ↗
Journal ArticleCited in: Work, Education, Disability, Carer Support, and Access to Care - [138]
Tuller D, Vink M. “Graded exercise therapy and cognitive behavior therapy do not improve employment outcomes in ME/CFS.” Work (Reading, Mass.) (2023). PMID: 36911962 ↗
Journal ArticleCited in: Work, Education, Disability, Carer Support, and Access to Care - [139]
Hartley G, Purrington J. “Service users' and parents/carers' experiences of a paediatric chronic fatigue service: A service evaluation.” Chronic illness (2023). PMID: 37231733 ↗
Journal ArticleCited in: Work, Education, Disability, Carer Support, and Access to Care - [140]
Cousins O, Leeming H, Putrino D et al.. “A new patient-led approach to building research infrastructure and evidence generation.” Oxford open immunology (2026). PMID: 42261335 ↗
Journal ArticleCited in: Long-Term Course, Prognosis, Follow-Up, and Research Priorities - [141]
Abken E, Tyson S, Kingdon C. “Overcoming barriers in myalgic encephalomyelitis/chronic fatigue syndrome research: the CureME participatory model.” Frontiers in human neuroscience (2026). PMID: 42483535 ↗
Journal ArticleCited in: Long-Term Course, Prognosis, Follow-Up, and Research Priorities - [142]
Kabir F, Yin KN, Jeffree MS et al.. “Effectiveness of adapted physical activity and therapeutic exercise programme in improving chronic fatigue syndrome in long COVID, delivered via hospital-based rehabilitation versus telerehabilitation.” Trials (2026). PMID: 42310705 ↗
Journal Article, Randomized Controlled Trial, Comparative StudyCited in: Long-Term Course, Prognosis, Follow-Up, and Research Priorities